Liquid biopsy in pancreatic cancer: Are we ready to apply it in the clinical practice?
Entidad
UAM. Departamento de MedicinaEditor
MDPIFecha de edición
2021-04-20Cita
10.3390/cancers13081986
Cancers 13.8 (2021): 1986
ISSN
2072-6694DOI
10.3390/cancers13081986Versión del editor
https://doi.org/10.3390/cancers13081986Materias
CTCs; CtDNA; Exosomes; Liquid biopsy; MiRNAs; Pancreatic ductal adenocarcinoma; MedicinaDerechos
© 2021 by the authorsResumen
Pancreatic ductal adenocarcinoma (PDAC) exhibits the poorest prognosis of all solid tumors, with a 5-year survival of less than 10%. To improve the prognosis, it is necessary to advance in the development of tools that help us in the early diagnosis, treatment selection, disease monitoring, evaluation of the response and prognosis. Liquid biopsy (LB), in its different modalities, represents a particularly interesting tool for these purposes, since it is a minimally invasive and risk-free procedure that can detect both the presence of genetic material from the tumor and circulating tumor cells (CTCs) in the blood and therefore distantly reflect the global status of the disease. In this work we review the current status of the main LB modalities (ctDNA, exosomes, CTCs and cfRNAs) for detecting and monitoring PDAC
Lista de ficheros
Google Scholar:Heredia-Soto, Victoria
-
Rodríguez Salas, Nuria
-
Feliú Batlle, Jaime
Lista de colecciones del ítem
Registros relacionados
Mostrando ítems relacionados por título, autor, creador y materia.
-
Identification of carcinogenesis and tumor progression processes in pancreatic ductal adenocarcinoma using high-throughput proteomics
Trilla-Fuertes, Lucía; Gámez Pozo, Angelo; Lumbreras-Herrera, María Isabel; López-Vacas, Rocío; Heredia-Soto, Victoria; Ghanem, Ismael; López-Camacho, Elena; Zapater-Moros, Andrea; Miguel, María; Peña-Burgos, Eva M.; Palacios, Elena; de Uribe, Marta; Guerra, Laura; Dittmann, Antje; Mendiola, Marta; Vara, Juan Ángel Fresno; Feliú Batlle, Jaime
2022-05-13